John H. Zhang – författare

Primer on Cerebrovascular Diseases, Second Edition, is a handy reference source for scientists, students, and physicians needing reliable, up-to-date information on basic mechanisms, physiology, pathophysiology, and medical issues related to brain vasculature. The book consists of short, specific chapters written by international experts on cerebral vasculature, presenting the information in a comprehensive and easily accessible manner.

Numerous changes have occurred in the field since the publication of the first edition in 1997, particularly our understanding of the genetic aspects of cerebrovascular disease. This updated edition reflects the advances made over the last two decades, not only demonstrating the promise for therapy, but also for a molecular understanding of cerebrovascular diseases. The new edition includes new and expanded topics, including carotid stenting, Iatrogenic causes of stroke, axonal transport and injury, RNAIs, proteomics, and more.

2018 BMA Medical Book Awards Highly Commended in Neurology.

Provides concise chapters on topics in cerebral blood flow and metabolism, pathogenesis of cerebrovascular disorders, diagnostic testing, and management in a comprehensive and accessible format Written by international leading authorities on cerebral vasculature Provides up-to-date information on practical applications of basic research and the main clinical issues facing the community, such as axonal transport and proteomics

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research. The emphasis is placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.

Stroke is a major cause of death and disability in the U.S. and worldwide. A variety of pathophysiologic episodes or cellular medications occur following a stroke, and knowledge of these aftermath events can lead to potential therapeutic strategies that may reverse or attenuate stroke injury. Cellular events that occur following stroke include the excessive releases of excitatory amino acids, alterations in the genomic responses, mitochondrial injury producing reactive oxygen and nitrogen species (ROS), and secondary injury, often in the setting of reperfusion.

Cerebral preconditioning is a phenomenon wherein a mild insult or stress induces cellular and tissue adaptation or tolerance to a later, severe injury, therefore reflecting the efficacy of endogenous mechanisms of cerebrovascular protection. Initially identified for rapid cardiac protection, preconditioning has expanded to all aspects of CNS protection from ischemia, trauma and potentially neurodegeneration. Many different stimuli or stressors have been identified as preconditioning agents, suggesting a downstream convergence of mechanisms and underscoring the potential for translational application of preconditioning in the clinic. Moreover, the fundamental mechanisms responsible for preconditioning-induced tolerance will help in the design novel pharmacological approaches for neuroprotection. While stroke and many other brain injuries are not predictable, in some populations (e.g., metabolic syndrome, patients undergoing carotid endarterectomy, aneurysm clipping, or with recent TIAs) the risk for stroke is identifiable and significant, and preconditioning may represent a useful strategy for neuroprotection. For unpredictable injuries, post-conditioning the brain – or inducing endogenous protective mechanisms after the initial injury – can also abrogate the extent of injury. Finally, remote pre- and post-conditioning methods have been developed in animals, and are now being tested in clinical trials, wherein a brief, noninjurious stress to a noncerebral tissue (i.e., skeletal muscle) can provide protection to the CNS and thereby allows clinicians the opportunity to circumvent concerns regarding the direct preconditioning of neurological tissues.

Recent research has revealed the importance of immunological mechanisms and inflammation in delaying damage and/or promoting repair after an acute injury to the central nervous system.  This book provides a comprehensive and up-to-date overview of the role of immunological mechanisms and therapies for treating acute neurological injuries such as cerebral ischemia, hemorrhage, and brain and spinal cord trauma. In several sections, the contributing authors provide a review of immunological mechanisms involved in neurological injury and of various translational and clinical research aimed at harnessing those mechanisms for better patient outcomes.​

White matter injury can result from both ischemic and hemorrhagic stroke as well as a host of other CNS diseases and conditions such as neonatal injuries, neurodegenerative disorders including Alzheimer's disease, traumatic brain injuries, carbon monoxide poisoning, and drug or alcohol overdoses. The extent of white matter injury is extremely important to patient outcomes. Several recent technological developments including advanced neuroimaging and the breeding of new rodent models of white matter injury have provided growing insight into initial damage and repair after a stroke or other damaging event. The proposed book will be the first to provide a systematic expert summary of normal white matter morphology as well as white matter injury following stroke and other CNS injuries.

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research.

Cellular events that occur following stroke include the excessive releases of excitatory amino acids, alterations in the genomic responses, mitochondrial injury producing reactive oxygen and nitrogen species (ROS), and secondary injury, often in the setting of reperfusion.

Cerebral preconditioning is a phenomenon wherein a mild insult or stress induces cellular and tissue adaptation or tolerance to a later, severe injury, therefore reflecting the efficacy of endogenous mechanisms of cerebrovascular protection.

Recent research has revealed the importance of immunological mechanisms and inflammation in delaying damage and/or promoting repair after an acute injury to the central nervous system.  This book provides a comprehensive and up-to-date overview of the role of immunological mechanisms and therapies for treating acute neurological injuries such as cerebral ischemia, hemorrhage, and brain and spinal cord trauma. In several sections, the contributing authors provide a review of immunological mechanisms involved in neurological injury and of various translational and clinical research aimed at harnessing those mechanisms for better patient outcomes.​

White matter injury can result from both ischemic and hemorrhagic stroke as well as a host of other CNS diseases and conditions such as neonatal injuries, neurodegenerative disorders including Alzheimer's disease, traumatic brain injuries, carbon monoxide poisoning, and drug or alcohol overdoses. The extent of white matter injury is extremely important to patient outcomes. Several recent technological developments including advanced neuroimaging and the breeding of new rodent models of white matter injury have provided growing insight into initial damage and repair after a stroke or other damaging event. The proposed book will be the first to provide a systematic expert summary of normal white matter morphology as well as white matter injury following stroke and other CNS injuries.

The successful previous volume on this topic provided a detailed benchwork manual for the most commonly used animal models of acute neurological injuries including cerebral ischemia, hemorrhage, vasospasm, and traumatic brain and spinal cord injuries.

The successful previous volume on this topic provided a detailed benchwork manual for the most commonly used animal models of acute neurological injuries including cerebral ischemia, hemorrhage, vasospasm, and traumatic brain and spinal cord injuries.

The successful previous volume on this topic provided a detailed benchwork manual for the most commonly used animal models of acute neurological injuries including cerebral ischemia, hemorrhage, vasospasm, and traumatic brain and spinal cord injuries.  Animal Models of Acute Neurological Injuries II: Injury and Mechanistic Assessments aims to collect chapters on assessing these disorders from cells and molecules to behavior and imaging. These comprehensive assessments are the key for understanding disease mechanisms as well as developing novel therapeutic strategies to ameliorate or even prevent damages to the nervous system.  Volume 1 examines general assessments in morphology, physiology, biochemistry and molecular biology, neurobehavior, and neuroimaging, as well as extensive sections on subarachnoid hemorrhage, cerebral vasospasm, and intracerebral hemorrhage.  Designed to provide both expert guidance and step-by-step procedures, chapters serve to increase understanding in what, why, when, where, and how a particular assessment is used. Accessible and essential, Animal Models of Acute Neurological Injuries II: Injury and Mechanistic Assessments will be useful for trainees or beginners in their assessments of acute neurological injuries, for experienced scientists from other research fields who are interested in either switching fields or exploring new opportunities, and for established scientists within the field who wish to employ new assessments.

The successful previous volume on this topic provided a detailed benchwork manual for the most commonly used animal models of acute neurological injuries including cerebral ischemia, hemorrhage, vasospasm, and traumatic brain and spinal cord injuries.  Animal Models of Acute Neurological Injuries II: Injury and Mechanistic Assessments aims to collect chapters on assessing these disorders from cells and molecules to behavior and imaging. These comprehensive assessments are the key for understanding disease mechanisms as well as developing novel therapeutic strategies to ameliorate or even prevent damages to the nervous system.  Volume 2 examines global cerebral ischemia, focal cerebral ischemia, and neonatal hypoxia-ischemia, as well as intensive sections covering traumatic brain injury and spinal cord injury.  Designed to provide both expert guidance and step-by-step procedures, chapters serve to increase understanding in what, why, when, where, and how a particular assessment is used. Accessible and essential, Animal Models of Acute Neurological Injuries II: Injury and Mechanistic Assessments will be useful for trainees or beginners in their assessments of acute neurological injuries, for experienced scientists from other research fields who are interested in either switching fields or exploring new opportunities, and for established scientists within the field who wish to employ new assessments.

This book highlights the latest developments in acute and delayed neurovascular injury studies including delayed cerebral vasospasm, early brain injury, micro-circulation compromise, spreading cortical depolarization, neuroinflammation, and long-term cognitive dysfunctions after subarachnoid hemorrhage.

This volume is focused on subjects related to cerebral ischemia and reperfusion injuries after acute stroke. All chapters are selected from the Sixth Elite Stroke meeting named Pangu Stroke Conference and written by members of world leading laboratories of stroke studies. The contents cover both clinical and bench studies, from basic components of cerebral arterial system to clinical reperfusion injury cases, from reperfusion caused programmed cell death and astrocyte activation to oxidative stress and nitric oxide after reperfusion, from extracellular matrix and inflammation to a role of diabetes after reperfusion, from small artery disorders to collateral circulation and blood pressure control after reperfusion. Wei-Jian Jiang, Chairman of New Era Stroke Care and Research Institute of PLA Rocket Force General Hospital, Beijing, China. Wengui Yu, Professor and Director of Comprehensive Stroke & Cerebrovascular Center, University of California, Irvine YanQu, Professor and Director of Neurosurgery at the Second Affiliated Hospital of Air Force Medical University, Xi’an, China. Zhongsong Shi, Professor of Neurosurgery at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Ben-yan Luo, Professor and Chair of Neurology at the First Affiliated Hospital of Zhejiang University. John H. Zhang, Professor of Anesthesiology and Physiology at Loma Linda University School of Medicine, Loma Linda, CA, USA.

The second edition continues to offer the research community tested approaches for this area of investigation. As with the first edition, top experts have developed and contributed these animal models.

The blood-brain-barrier serves to encapsulate and protect the central nervous system, but it also presents a major barricade to therapeutic drug delivery. Poor penetration is the most common hurdle to translating a promising experimental therapy that uses invasive delivery methods to a clinically useful application. In the last 10 years, intranasal delivery of various therapeutic compounds including small chemicals, large proteins, and even stem cells has proven to be very effective in bypassing the blood-brain-barrier and has led to some important advances in translational research for stroke and other neurological diseases. The proposed book will bring together reports from various labs around the world who have had successes in pre-clinical studies of intranasal therapies for various diseases including adult and perinatal stroke, Alzheimer's, Parkinson's, and others.​

Cellular therapy for stroke and neural trauma has gained worldwide attention during the last decade and has shown some promising results. Various cells, including neural stem cells, bone marrow stem cells, endothelial progenitor cells, and many others have had protective or regenerative effects in animal models. The proposed book will address recent research on all relevant cell types.  In addition, it will provide information on cell isolation and culture skills, transplantation methods, and neurological functional evaluations. This is the first book to focus on cellular therapy for stroke and other CNS injuries.

In this book, leading world authorities on brain edema and neurological disorders/injuries and experts in preconditioning join forces to discuss the latest progress in basic sciences, translational research, and clinical management strategies relating to these conditions. The range of topics covered is wide, including microglia, energy metabolism, trace metals and ion channels, vascular biology, cellular treatment, hemorrhagic stroke, novel technological advances, anesthesia and medical gases, pediatric brain edema, neuroimaging, behavioral assessment, clinical trials, peripheral to central signaling pathways, preconditioning translation, and animal models for preconditioning and brain edema research. The book comprises presentations from Brain Edema 2014, the joint meeting of the 16th International Conference on Brain Edema and Cellular Injury and the 3rd Symposium on Preconditioning for Neurological Disorders, held in Los Angeles on September 27–30, 2014.

This book provides a comprehensive overview of the latest research in the role of non-neuronal cells - astrocytes, oligodendrocytes, endothelial cells, pericytes, microglia, and other immune cells in ischemic brain injury and long-term recovery. In these cases, neurodegeneration and brain repair are controlled in a sophisticated system, incorporating interactions between different cell types and cellular systems. Also explored are the therapeutic strategies that target non-neuronal responses after stroke and their translational potentials.

In this book, leading world authorities on brain edema and neurological disorders/injuries and experts in preconditioning join forces to discuss the latest progress in basic sciences, translational research, and clinical management strategies relating to these conditions.

Cellular therapy for stroke and neural trauma has gained worldwide attention during the last decade and has shown some promising results. Various cells, including neural stem cells, bone marrow stem cells, endothelial progenitor cells, and many others have had protective or regenerative effects in animal models. The proposed book will address recent research on all relevant cell types.  In addition, it will provide information on cell isolation and culture skills, transplantation methods, and neurological functional evaluations. This is the first book to focus on cellular therapy for stroke and other CNS injuries.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases.

This book discusses recent advances in the field of translational stroke research. The editors have designed the book to provide new insight into the importance of regeneration and repair mechanisms for stroke victims. The editors have brought together a talented group of international stroke researchers and clinicians to contribute to this volume, which is written for students, researchers and physicians in biotechnology, neurosciences, neurology, neuroradiology and neurosurgery.Throughout the world, stroke is still a leading cause of mortality and morbidity; there are 152,000 strokes in the United Kingdom, 62,000 in Canada, and approximately 15 million people worldwide. Large communities of stroke survivors are eagerly awaiting scientific advances in translational stroke research related to regeneration and recovery of function that would offer new therapeutics for rehabilitation and regeneration utilizing novel stem cell and molecular-based approaches. This volume will allow the reader to undersnd the future of stroke treatment from its inception in the laboratory through to clinical trial design. The reader will learn about the recent advances made in these areas related to basic and applied stroke research and their translational potential.Dr. Paul A. Lapchak is Professor of Neurology and Director of Translational Research in the Departments of Neurology & Neurosurgery at Cedars-Sinai Medical Center in Los Angeles CA, USA.  Dr. Lapchak is an internationally recognized expert conducting translational drug development research for ischemic and hemorrhagic stroke. Dr. John H. Zhang is Professor of Anesthesiology, Neurosurgery, Neurology, and Physiology, and Director, Center for Neuroscience Research at Loma Linda University School of Medicine, Loma Linda, CA, USA. Dr. Zhang is an internationally recognized expert working on drug development for hemorrhagic stroke.

This book provides a comprehensive overview of the latest research in the role of non-neuronal cells - astrocytes, oligodendrocytes, endothelial cells, pericytes, microglia, and other immune cells in ischemic brain injury and long-term recovery.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases.

This book discusses recent advances in the field of translational stroke research. The editors have designed the book to provide new insight into the importance of regeneration and repair mechanisms for stroke victims. The editors have brought together a talented group of international stroke researchers and clinicians to contribute to this volume, which is written for students, researchers and physicians in biotechnology, neurosciences, neurology, neuroradiology and neurosurgery.Throughout the world, stroke is still a leading cause of mortality and morbidity; there are 152,000 strokes in the United Kingdom, 62,000 in Canada, and approximately 15 million people worldwide. Large communities of stroke survivors are eagerly awaiting scientific advances in translational stroke research related to regeneration and recovery of function that would offer new therapeutics for rehabilitation and regeneration utilizing novel stem cell and molecular-based approaches. This volume will allow the reader to undersnd the future of stroke treatment from its inception in the laboratory through to clinical trial design. The reader will learn about the recent advances made in these areas related to basic and applied stroke research and their translational potential.Dr. Paul A. Lapchak is Professor of Neurology and Director of Translational Research in the Departments of Neurology & Neurosurgery at Cedars-Sinai Medical Center in Los Angeles CA, USA.  Dr. Lapchak is an internationally recognized expert conducting translational drug development research for ischemic and hemorrhagic stroke. Dr. John H. Zhang is Professor of Anesthesiology, Neurosurgery, Neurology, and Physiology, and Director, Center for Neuroscience Research at Loma Linda University School of Medicine, Loma Linda, CA, USA. Dr. Zhang is an internationally recognized expert working on drug development for hemorrhagic stroke.